Free Trial
→ Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why (From Banyan Hill Publishing) (Ad)tc pixel

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up - Here's Why

Written by MarketBeat
Updated August 19, 2025
Ascentage Pharma Group International logo with Medical background

Key Points

  • Ascentage Pharma Group International shares gapped up from $41.15 to $42.45 at market open, indicating positive market sentiment.
  • The company has a debt-to-equity ratio of 3.24, signaling a high level of debt relative to equity.
  • A number of hedge funds have recently increased their stakes in Ascentage, with total reported investments exceeding $4.7 million across several firms.
  • Five stocks to consider instead of Ascentage Pharma Group International.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $41.15, but opened at $42.45. Ascentage Pharma Group International shares last traded at $42.45, with a volume of 2,663 shares trading hands.

Ascentage Pharma Group International Stock Down 2.3%

The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26. The firm has a fifty day moving average of $38.85.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Chevy Chase Trust Holdings LLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter worth $227,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $391,000. Tema Etfs LLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $610,000. Finally, Monashee Investment Management LLC purchased a new stake in shares of Ascentage Pharma Group International in the first quarter worth about $3,511,000.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

See Also

Should You Invest $1,000 in Ascentage Pharma Group International Right Now?

Before you consider Ascentage Pharma Group International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.

While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.